February 27, 2023
Payers | Tea Leaves
  • Payers should be keeping a close eye on developments in the drug pipeline for Alzheimer’s disease therapies—and how the Centers for Medicare & Medicaid Services (CMS) responds to those developments, according to a new report from Optum. The report highlighted two monoclonal antibody drugs that target beta-amyloid plaques to treat Alzheimer’s: lecanemab and donanemab. Optum’s report notes that lecanemab, developed by Biogen and Eisai, secured accelerated approval from the FDA in January. Although Eli Lilly’s donanemab was rejected, the company has already filed for traditional FDA approval and expects to have the data necessary to follow suit in the second quarter of this year, according to the report. (Article here)